AU8323191A - Creation of Inventions and Patents with Artificial Intelligence

AU8323191A – R(+)-terazosin
– Google Patents

AU8323191A – R(+)-terazosin
– Google Patents
R(+)-terazosin

Info

Publication number
AU8323191A

AU8323191A
AU83231/91A
AU8323191A
AU8323191A
AU 8323191 A
AU8323191 A
AU 8323191A
AU 83231/91 A
AU83231/91 A
AU 83231/91A
AU 8323191 A
AU8323191 A
AU 8323191A
AU 8323191 A
AU8323191 A
AU 8323191A
Authority
AU
Australia
Prior art keywords
tetrahydro
furanyl
enantiomer
carbonyl
quinazolinamine
Prior art date
1990-06-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Application number
AU83231/91A
Other versions

AU654148B2
(en

Inventor
Bruce W Horrom
John J Kyncl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Abbott Laboratories

Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1990-06-29
Filing date
1991-06-26
Publication date
1992-01-23

1991-06-26
Application filed by Abbott Laboratories
filed
Critical
Abbott Laboratories

1992-01-23
Publication of AU8323191A
publication
Critical
patent/AU8323191A/en

1994-10-27
Application granted
granted
Critical

1994-10-27
Publication of AU654148B2
publication
Critical
patent/AU654148B2/en

2011-06-26
Anticipated expiration
legal-status
Critical

Status
Ceased
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07D—HETEROCYCLIC COMPOUNDS

C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings

C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P25/00—Drugs for disorders of the nervous system

A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P9/00—Drugs for disorders of the cardiovascular system

A61P9/12—Antihypertensives

Abstract

R(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethox y-4-quinazolinamine hydrochloride or a pharmaceutically acceptable salt or hydratet hereof (terazosin), substantially free of the S(-)-enantiomer.

Description

R(+)-Terazosin Cross-Reference to Related Applications
This application is a continuation-in-part of co-pending application Serial No. 546,349 filed 29 June 1990.
Technical Field
This invention relates to compounds having pharmacological activity, to pharmaceutical compositions containing such compounds and to medical methods of treatment. More particularly, this invention concerns R(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-pipera2dnyl]-6,7-dimethoxy- 4-quinazolinamine, substantially free of the S(-)-enantiomer, its pharmaceutically acceptable salts and hydrates, to pharmaceutical compositions containing the compound, and to medical methods of treatment employing the compound.
Background of the Invention
The adrenergic nervous control of bodily functions is mediated by two hormones:
norepinephrine, which is generated in the adrenergic nerves and released from their endings, and epinephrine, which is synthesized in the adrenal medulla and secreted into circulating blood. Both of these hormones act by binding to special receptors, designated as “adrenergic” receptors, which mediate the signal of the hormones to the intracellular biochemical mechanisms leading to stimulation of diverse physiological functions. Such functions include contraction of vascular smooth muscle (which can increase blood pressure), acceleration of heart rate, induction of metabolic changes in the liver, modulation of central nervous system activity, and many others.
The adrenergic receptors are proteins embedded in celluler membranes having unique, specific amino acid sequences. Four general families of adrenergic receptors have been identified and designated α1 , α2, β1 and β2, all of which can be stimulated by norepinephrine and epinephrine. These receptor families, however, differ such that specific agents have been developed which can selectively stimulate or inhibit each type of receptor. The degree and type of receptor selectivity for a particular agonist or antagonist agent is an important pharmacological property of such an agent and can have substantial impact on its biological activity, side effects and safety. In general, excessive stimulation of the α1 adrenoreceptor is a hallmark of numerous pathological situations and disease states such as hypertension, congestive heart failure, cardiac hyperplasia, benign prostatic hyperplasia, hyperinsulinemia, lipid disorders, impotency, as well as many others.

Importantly, the α2 adrenoreceptors, which are very similar to the α1 species, regulate the release of the two adrenergic hormones, norepinephrine and epinephrine, and impact on the overall level of adrenergic activity. The stimulation of α2 receptors by an agonist inhibits the secretion of norepinephrine and epinephrine, whereas α2 antagonist activity increases the secretion of these hormones substantially. Thus, the α1/ α2 adrenoreceptor selectivity of an α-antagonist is very important and a desirable feature.
A number of non-selective α-adrenergic blockers, such as phenoxybenzamine and phentolamine, have prominent effects on both α1 and α2 receptors. It is the α2 component of their adrenergic receptor activity which increases the adrenergic hormone secretion and thus limits their therapeutic use. Typical of such α2 antagonist effects are increases in plasma catecholamine levels, increases in heart rate and contractility, and other highly undesirable therapeutic phenomena.
It is therefore desirable to obtain α1 blocking agents which have greater α1/ α2 selectivity than agents currently available. Such selectivity permits treatment of diseases characterized by elevated α1 adrenergic activity without stimulating α2 adrenoreceptor-mediated secretion of norepinephrine and epinephrine.
2-[4-[(Tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4 -quinazolinamine, also commonly known by its generic name, terazosin, has been known for several years as an antihypertensive drug. United States Patent 4,026,894 discloses and claims the compound and United States Patent 4,112,097 discloses and claims pharmaceutical compositions containing the compound and a method of treating hypertensign in mammals. United States Patent 4,251 ,532 discloses and claims the dihydrate of the hydrochloride salt of terazosin. The latter patent also discloses and claims pharmaceutical compositions comprising the hydrochloride dihydrate and a method of treating hypertension. While the terazosin molecule possesses a single chiral center, and can thus exist in two enantiomeric forms, none of these patents discusses this optical property of the molecule or mentions the two enantiomers.
In 1987, Nagatomo and coworkers reported the binding of the racemic compound and the individual enantiomers to α-receptors in dog brain and aorta tissue (Nagatomo, et al., Chem.
Pharm. Bull.. 35(4): 1629-1632 (1987)). Their data indicate that, while both enantiomers and the racemic compound bind selectively to the α1 receptors, little difference appeared to exist between the degrees of selectivity of the two enantiomers for α1 receptors over α2 receptors. This article did not report any data to indicate the optical purity of the materials employed.
Summary of the Invention
It has now been found that the two enantiomeric forms of 2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine (terazosin) can be resolved, and a significant difference exists in the degree of selective binding the the R(+)- and S(-)-

enantiomers at the α-adrenergic receptors, resulting in important unexpected pharmacological properties and in their toxicity. The lack of affinity of the R(+)-enantiomer of terazosin for the 012 receptors compared to that of either the S(-)-enantiomer or the racemic compound is believed to confer advantages on the R(+)-enantiomer as a pharmaceutical agent
The present invention thus provides, in one embodiment, the compound R(+)-2-[4- [(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine, its
pharmaceutically acceptable salts and hydrates, substantially free of the S(-) enantiomer.
In another embodiment, there are provided pharmaceutical compositions comprising a therapeutically effective amount of R(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7- dimethoxy-4-quinazolinamine, a pharmaceutically acceptable salt and/or hydrate thereof, substantially free of the S(-)-enantiomer, in combination with a pharmaceutically acceptable carrier.
In a further embodiment of the present invention there is provided a method for treating disease states characterized by abnormally elevated levels of α1 adrenergic activity, particularly hypertension, congestive heart failure, hyperinsulinemia and benign prostatic hyperplasia, in a mammal in need of such treatment comprising administering a therapeutically effective amount of R(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamin pharmaceutically acceptable salt orhydrate thereof substantially free of the S(-)-enantiomer.
Detailed Description
R(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine or a pharmaceutically acceptable salt and/or hydrate thereof, substantially free of the S(-)-enantiomer has utility for the treatment or amelioration of disease states which are modulated by α-adrenergic receptor blocking agents. These disease states are recognized in the literature to include hypertension, congestive heart failure, cardiac arrhythmia, pulmonary hypertension, arterioconstriction, and benign prostatic hyperplasia (see, for example, W. H.
Frishman and Shlomo Charlap, “Adrenergic Receptors as Pharmacological Targets: The AlphaAdrenergic Blocking Drugs,” Chapter 4 in Adrenergic Receptors in Man, Paul A. Insel, Ed., Marcel Dekker, Inc., New York.
The term “pharmaceutically acceptable salts” refers to the relatively non-toxic, inorganic and organic acid addition salts of the compound of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, laurylsulphonate salts and the like. (See, for

example S. M. Berge, et al., “Pharmaceutical Salts,” J. Pharm. Sci.. 66: 1-19 (1977) which is incorporated herein by reference.) The particularly preferred salt of this invention is the hydrochloride.
In accordance with the present invention, the two enantiomers have now been substantially completely resolved, and the optical rotations of the base form of the compound have been found to be [a]D 22 = 34.83º (C=1, 3N hydrochloric acid) for the R(+)-enantiomer and [a]D 22 = -26.9º
(C=1, 3N hydrochloric acid) for the S(-)-enantiomer. Conversion of the base forms of the two enantiomers to the hydrochloride salt dihydrate forms has produced materials having optical rotations of [a]D 28.5 = +23.9º (C=1, H2O) or greater for the dextrorotatory (i.e. R(+)) enantiomer and [a]D 28.5 = -23.1º (C=1, H2O) for the levorotatory (i.e. S(-)) enantiomer. Further purification of the R(+)-enantiomer hydrochloride dihydrate has produced material having an optical rotation of [a]D 24 = +25.3º (C=1, H2O).5
The binding affinity of the substantially completely resolved enantiomers of terazosin for the α1 and 02 adrenoreceptors (including the α2A and α2B receptor subtypes) was measured using standard techniques and the results are presented below in Table 1. It is known that more than one species of 02 adrenoreceptor can be differentiated in different tissues (D. B. Bylund, Pharmacol. Biochem. & Behavior, 22: 835-843 (1985). For example, human platelets have been recognized to contain an almost pure population of a sub-type of 02 adrenoreceptor designated α2A, whereas neonatal rat lung cellular membranes contain an 02 adrenoreceptor subtype which has been designated α2B. The cellular membranes of rat cerebral cortex have roughly equal numbers of α2 adrenoreceptors of both the α2A and α2B subtypes.
Binding of a compound at α1 and α2 receptor sites is typically determined by allowing the test compound to compete with radiolabeled compounds which are known to selectively bind at each site. The technique is well known and described in the literature. The pKI, or negative logarithm of the binding equilibrium constant, is determined from the experimental data for each receptor and the degree of selectivity of the compound in question for α1 over α2 receptors can be measured by the antilogarithm of the differences between the pKI values for the two receptors. α1 Adrenergic binding data were obtained for the two enantiomers of terazosin and the racemic compound. Tissue from the liver and cerebral cortex of male Sprague-Dawley rats was homogenized in ice-cold assay buffer (Tris-HCl, 50 mM, pH 7.0 and 22°C) . After centrifugation at 48,000 g for ten minutes the resulting pellets, containing cellular membranes containing α-receptors, were resuspended in 20 volumes of assay buffer and recentrifuged for ten minutes at 48,000 g. Liver membranes were diluted 200-fold and cerebral cortex tissues 50-fold with assay buffer.

Binding to α1 adrenergic receptors was characterized with liver membranes in competition studies using tritiated prazosin (82 Ci/mmol, DuPont NEN; 0.2 nM) and six concentrations of each test compound at half-log incremental concentrations. Binding to α2 adrenergic receptors was characterized in cerebral cortex tissue using tritiated rauwolscine (82.2 Ci/mMol, DuPont NEN; 0.5 nM) and six concentrations of competing test compound. Equilibrium binding was characterized after a 50 minute incubation period at 22°C . Bound radioligand was separated from radioligand in solution by filtration under vacuum through Whatman 935 AH filters. After washing five times with ice-cold assay buffer, the filters were immersed in 3 ml of Ready-Solv EP Scintillation fluid (Beckman) and counted in a Beckman LS3801 counter for 10 minutes or to a preset counting error of 4.5% at 50% counting efficiency.
To determine α2A adrenoreceptor binding affinities, human platelets were harvested using the techniques described in the literature (Newman, et al., J. Clin. Invest., 61: 395-402 (1978); Hoffman, et al., Proc. Nat.. Acad. Sci. 77: 4569-4573 (1980); and Hoffman, et al.,
Endocrinology, 110: 926-932 (1982)) These harvested platelets were used as a source of α2A adrenoreceptors. Neonatal rat lung tissue was used as the source of α2B adrenoreceptors and was prepared by the techniques described by Bylund, et al., J. Pharm. Exp. Ther., 245: 600-607 (1988). Basically, in each instance, tissues were homogenized and a cell membrane fraction prepared and washed by centirfugation, with a final resuspension of the cell homogenate in 6.25 volumes of 25 mM glycylglycine buffer (pH 7.4) and stored in 2 ml aliquots at -80° C until used in the assay. Each assay was performed as described above, using 50 μL of compound, water, or 10-5M phentolamine (to define non-specific binding), plus 450 μL of tritiated rauwolscine
(approximately 0.2 nM) and 500 μL of tissue homogenate which, just prior to the assay was diluted with a further 12 volumes of gycylglycine buffer. The tube contents were mixed and allowed to equilibrate for two hours at 0º C. Radioligand bound to the receptors was separated from free radioligand using rapid filtration over Whatman GF/B filters. The retained tissue was rinsed with 45 mL washes of 50mM TRIS-HCl (pH 7.4) buffer. The filters were placed in individual scintillation vials, dried, and immersed in 3 mL of scintillation fluid. Radioactivity was determined using standard scintillation counting techniques.
The concentration at which 50% of the specifically bound radioligand was displaced by the test compound (IC50) was calculated and converted to an equilibrium dissociation constant (KI) using the formula:
Kι = IC50/(1 + [L]/KD)
where [L] is the concentration of radioligand and KD is the equilibrium dissociation constant of the radioligand for the receptor. The mean pKI values for the R(+), S(-), and racemic terazosin appear in Table 1.

Table 1
α-Adrenergic Binding of rαc-Terazosin
and Its Enantiomers
Cmpd. α1 α2A+2B α1/α2 α2A α1/ α2 α2B α1/α2
Receptor Receptor SelectReceptor SelectReceptor Select¬
Rat Rat ivity Human ivity Rat ivity Liver Cortex Ratio platelets Ratio Lung Ratio pKI PKI PKi pKI (±SEM) (±SEM) (±SEM) (±SEM)
R(+) 9.016 5.938 1,197 5.668 2,260 6.603 260
±0.083 ±0.178 ±0.033 ±0.041
Racemic 9.912 6.569 420 6.285 811 8.250 8.8
±0.101 ±0.129 ±0.052 ±0.078
S(-) 9.192 7.036 143 6.538 453 8.777 2.6
±0.112 ±0.199 ±0.039 ±0.119
*Antilog [pKI(α1)-pKI(α2)]
Examination of the data presented in Table 1 show that while R(+)-terazosin exhibited binding affinity for the α1 adrenoreceptor similar to that of the S(-)-enantiomer and racemate, the R(+)-enantiomer was more selective for the α1 adrenorecptor as indicated by the α1/α2 selectivity ratios for the two enantiomers and the racemate. The degree of selectivity of the R(+)-enantiomer over the S(-)-enantiomer or the racemate is more pronounced when the αι/α2 selectivity
ratiosvalues for the a2A and a2B adrenoreceptor subtypes are compared.
As discussed above, compounds which are active at α2 receptors are implicated in controlling the release of norepinephrine and related catecholamines. Thus, it is believed that R(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine possesses useful pharmaceutical properties while being less subject to undesirable side effects which flow from α2 -adrenergic binding activity.
The acute toxicities of the two enantiomeric forms of terazosin and the racemic compound were tested in adult male mice by intravenous administration, and the data appear in Table 2.

Table 2
Acute Toxicity
Compound LD50 mg/Kg 95% Confidence Statistical
Limits Significance
R(+) 306.6 265.8 – 445.1 Rac vs R(+) = p <0.05 Racemate 247.9 230.5 - 273.0 R(+) vs S(-) = p<0.05 S(-) 204.6 178.8 - 234.1 Rac vs S(-) = p<0.05 The data appearing in Table 2 show that R(+)-terazosin exhibits a roughly 50% higher LD50 (i.e. lower acute toxicity) than the corresponding S(-)-enantiomer. Racemic terazosin and the two enentiomers were tested for their effects on blood pressure and heart rate in unanesthetized spontaneously hypertensive (SH) rats, and the results are presented in Tables 3 and 4. The blood pressure of adult, male rats of the Okamoto strain to which the test compounds were administered, was measured by means of an automatically controlled pressure cuff attached to the base of the tail of each test animal. A photocell, placed distallly to the cuff sensed the arterial pulse wave. Five interference-free signals, obtained during deflation of the cuff were obtained for each rat. Only those rats having a systolic blood pressure in excess of 175 mm Hg during the control were employed in the study. Table 3 Effects of Terazosin on Blood Pressure in Spontaneously Hypertensive Rats Hours Dose Vehicle Racemate R(+) S (-) After (mg/Kg) % Change % Change % Change % Change Dosing from O- from O- from O- from O- Hour Hour Hour Hour Value Value Value Value (SEM) (SEM) (SEM) (SEM) 1 0.0 -1.32 (2.8) 1.0 -20.52 (1.6) -22.37 (1.7) -25.00 (1.7) 10.0 -36.18 (2.9) -28.58 (2.4) -31.81 (3.0) 5 0.0 -2.77 (2.5) 1.0 -8.82 (2.7) -6.42 (1.3) -27.25 (2.2) 10.0 -22.60 (1.9) -18.16 (2.4) -30.38 (2.8) Table 4 Effects of Terazosin on Heart Rate in Spontaneously Hypertensive Rats Hours Dose Vehicle Racemate R(+) S(-) After (mg/Kg) % Change % Change % Change % Change Dosing from O- from O- from O- from O- Hour Hour Hour Hour Value Value Value Value (SEM) (SEM) (SEM) (SEM) 1 0.0 -2.93 (2.9) 1.0 8.81 (6.7) -0.04 (3.5) 5.86 (3.2) 10.0 8.58 (6.0) -1.68 (3.5) 10.92 (5.2) 5 0.0 -9.96 (3.7) 1.0 -4.61 (3.8) -6.20 (2.5) -0.31 (4.7) 10.0 2.44 (6.5) -13.26 (3.3) 3.94 (5.4) The data in Table 3 shows that (R(+)-, S(-)- and racemic terazosin all produced similar lowering of blood pressure; however, the data in Table 4 show that R(+)-terazosin produced less effect on heart rate increase than either S(-)-terazosin or the racemate. The inhibition of α2 adrenoreceptors in vivo is known to facilitate the release of the neuronal transmitter, norepinopehrine, which in turn can cause an increase in cardiac contractility. In a further test, racemic terazosin and the two enantiomers were tested for their effects on the levels of plasma norepinephrine in anesthetized dogs, and the results appear in Table 5. Male beagle dogs weighing between 8.2 and 13.2 Kg were anesthetized with pentobarbital. Electrocardiogram leads were attached to the dogs and a lead 11 electrocardiogram was recorded. ASwan Ganz catheter was advanced into the pulmonary artey for measurement of pulmonary artery pressure and cardiac output. Central venous pressure was measured through the proximal port of the catheter. A dual tip micromanometer (Millar Model SPC-7707F) was advanced into the left ventricle of the heart for measurement of left ventricular pressure. The right femoral vein was cannulated for administration of the test compounds. Following a stabilization period of sixty minutes, vehicle (0.9% NaCl) was injected at a volume of 0.1 mg/Kg. Sixty minutes later, the lower dose (0.3 mg/kg) of the test compound was administered, followed sixty minutes later by the higher dose (3.0 mg/kg). The compounds were tested in fifteen dogs each, using a randomized schedule. The data in Table 5 show that there was no appreciable change in left ventricular contractility upon administration of the R(+)-enantiomer of terazosin, while administration of either the S(-)-enantiomer or the racemate produced measurable increases, even one hour after administration. The present invention also provides pharmaceutical compositions which comprise one or more of the compounds of formula I above formulated together with one or more non-toxic pharmaceutically acceptable carriers. The pharmaceutical compositions may be specially formulated for oral administration in solid or liquid form, for parenteral injection, or for rectal, vaginal, or topical administration. The pharmaceutical compositions of this invention can be administered to humans and other animals orally, rectally, parenterally , intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, or as an oral or nasal spray. The term "parenteral" administration as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion. Pharmaceutical compositions of this invention for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. These compositions may also contain adjuvants such as preservative, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like, Prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin. In some cases, in order to prolong the effect of the drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle. Injectable depot forms are made by forming microencapsuled matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly (orthoesters) and poly(anhydrides) Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues. The injectable formulations can be sterilized, for example, by filtration through a bacterialretaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use. Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or earner such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients. Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents. Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof. Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-iiritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound. Compounds of die present invention can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients, and the like. The preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology. Volume XIV, Academic Press, New York, N.Y. (1976), p. 33 et seq. Dosage forms for topical administration of a compound of this invention include powders, sprays, ointments and inhalants. The active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers, or propellants which may be required. Opthalmic formulations, eye ointments, powders and solutions are also contemplated as being within the scope of this invention. Actual dosage levels of active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active compound(s) that is effective to achieve the desired therapeutic response for a particular patient, compositions, and mode of administration. The selected dosage level will depend upon the activity of the particular compound, the route of administration, the severity of the condition being treated, and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required for to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. For use as an antihypertensive agent, the compound of this invention is generally dosed orally at levels of about 0.01 mg to about 250 mg, more preferably of about 0.1 mg to about 100 mg of active compound per kilogram of body weight per day to a mammalian patient. If desired, the effective daily dose may be divided into multiple doses for purposes of administration, e.g. two to four separate doses per day. Example 1 Preparation of R(+)-2-[4-[(tetrahydro-2-furanyl)carbonyn-1-piperazinyl]-6.7-dimethoxy-4- quinazolinamine from R(+)-tetrahydro-2-furoic acid resolved as the brucine salt Step 1 - Preparation of R(+)-tetrahydro-2-furoic acid Using the procedure detailed in Can. J. Chem.. 61:1383-1386 (1983), racemic terrahydro- 2-furoic acid was first converted to a mixture of the diastereomeric brucine salts by reaction with (-)-brucine in ethyl acetate. The crude brucine salt of R(+)-tetrahydro-2-furoic acid which first precipitated had a melting point of 191-197°C and an optical rotation [a]D 23 = -7.86° (C=1, methanol). The material was recrystallized three times from ethyl acetate to yield material melting at 200-203ºC and having an optical rotation [a]D 23ºC = -4.8º (C=1, methanol) (literature value[a]D = -5.8º (C=1, methanol)). The salt was acidified to recover R(+)-tetrahydro-2-furoic acid, b.p. 57-58°C at 0.1 mm Hg, refractive index, ηD 2 5 = 1.4953, optical rotation [a]D 22ºC = + 33.37° (C=1, chloroform) (literature value [a]D = + 30.4° (C=1, chloroform). Step 2 - Preparation of R(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy- 4-quinazolinamine R(+)-Tetrahydro-2-furoic acid was dissolved in tetrahydrofuran and 2.0 g (0.017 mole) of dicyclohexylcarbodiimide was added followed by 3.50 g (0.017 mole) N-hydroxysuccinimide. The mixture was stirred overnight at room temperature. The precipitated dicyclohexylurea which formed was collected by filtration and the residue washed with a small amount of tetrahydrofuran. The solid was discarded and the washings added to the filtrate. To the filtrate were added a solution of 4.91 g (0.017 mole) of 4-amino-6,7-dimethoxy-2-piperazinyl-4-quinazoline in tetrahydrofuran. The resulting mixture was stirred overnight at room temperature. The solid which had precipitated was collected by filtration and washed several times with tetrahydrofuran. The washings were combined with the filtrate which was evaporated to dryness. The residual solid was taken up in a 5/1 mixture of methylene chloride/methanol and the resulting mixture distilled to remove the methylene chloride. The removed methylene chloride was replaced by an equal volume of methanol, at which point the product began to crystallize from solution. The solution was allowed to cool to room temperature and stand for several hours, yielding R(+)-2-[4-[(tetrahydro-2-furanyl)cartbonyl]-1-piperazinyl]-6,7-dimethoxy-4- quinazolinamine, m.p.272-274'C, optical rotation [a]D 22ºC = 34.83° (C=1, 3N hydrochloric acid). Example 2 Preparation of R(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]- 1 -piperazinyn-6.7-dimethoxy-4-quinazolinamine. hydrochloride salt dihydrate R(+)-Terazosin hydrochloride salt dihydrate was prepared by heating an ethanol solution of R(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]- 1 -piperazinyl]-6,7-dimethoxy-4-quinazolinamine to near reflux and adding slightly more than one equivalent of concentrated aqueous hydrochloric acid. Solution occurred immediately, and the mixture was allowed to cool to room temperature and stand for several hours. The precipitate which formed was collected by filtration, washed with ethanol, and dried to yield R(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine, hydrochloride salt dihydrate having a melting point of 260.5-263.5°C and an optical rotation [a]D 28.5ºC = +23.94° (C=1, water). Example 3 Preparation of R(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1 -piperazinvn-6.7-dimethoxy-4- quinazolinamine hydrochloride dihydrate from enzvmatieallv resolved tetrahvdro-2-furoic acid Step 1 - Preparation of the benzyl ester of racemic tetrahydrofuroic acid (R,S)-Tetrahydro-2-furoic acid (1.152 kg, 10.1 mol) was dissolved in 5 liters of dichloromethane. Benzyl alcohol (1.08 kg, 10 mol) was added, followed by 10 ml of concentrated sulfuric acid. The resulting mixture was heated to reflux and maintained at that temperature, with azeotropic distillation of water derived from the reaction. When the calculated amount of water had been collected, the reaction mixture was cooled to room temperature and washed with 1 liter of 5% aqueous sodium bicarbonate solution and twice with 1 liter portions of water. The solution was then dried over anhydrous magnesium sulfate, filtered, and concentrated under vacuum to yield 1.9 kg of tetrahydro-2-furoic acid benzyl ester which was found to be 92% pure by chromatographic analysis. Step 2 - Enzymatic resolution of tetrahydro-2-furoic acid Tetrahydro-2-furoic acid benzyl ester (412 g, 2.0 mol) was mixed with 5 liters of 0.1 M phosphate buffer and the pH adjusted to 7.0 with sodium hydroxide solution. Prozyme® 6 enzyme (10 g, Amano International Enzyme Co., Inc., P.O. Box 1000, Troy, VA 22974, Lot No. PR002511P) was added to the solution in one portion. The pH of the resulting mixture was maintained at pH 6.84-7.03 by means of a pH Stat adding 2M sodium hydroxide solution. The mixture was allowed to react under these conditions overnight Chloroform (500 ml) was added to quench the reaction and the mixture was stirred for an additional fifteen minutes, after which it was filtered through diatomaceous earth to remove insoluble material. The aqueous phase was extracted twice with 500 ml portions of chloroform, and the chloroform solutions were combined, dried, and evaporated. The residue was taken up in 2 liters of diethyl ether and washed twice with 500 ml portions of water, twice with 5% aqueous sodium bicarbonate, and twice with water. The ether solution was then dried over anhydrous magnesium sulfate, filtered, and the solvent evaporated to yield a water-white oil. This material was distilled under reduced pressure to yield 1.45 g of (S)-tetrahydro-2- furoic acid, b.p. 102-105°C at 0.25 mm Hg. Hydrogenolysis of this material under standard conditions followed by distillation under reduced pressure afforded 72.73 g of (S)-tetrahydro-2- furoic acid in two fractions: Fraction 1: 35.93 g; b.p.72°C at 0.25 mm Hg; ηD 25 = 1.4595; [a]D25 = -33.87° (C = 1, CHCl3); Fraction 2: 36.8 g; 35.93 g; b.p. 72°C at 0.25 mm Hg; ηD 25 = 1.4595; [a]D 25 = -33.07° (C = 1, CHCI3). The original aqueous phase from the enzymatic reaction was concentrated to dryness under reduced pressure to yield a yellow/brown solid. This residue was taken up in 500 ml of water and 100 g of potassium acid phosphate were added. The resulting mixture was cooled over ice for thirty minutes after which 85% phsophoric acid was added to a pH of 2.0. The aqueous phase was extracted with three 500-ml portions of diethyl ether and the combined ether extracts were dried over anhydrous magnesium sulfate and evaporated to dryness to yield a water-white oil. Reduced pressure distillation of this oil yielded 155 g of prodiminantly (R)-tetτahydro-2-furoic acid, contaminated with the (S)-enantiomer (b.p. 65.0°C at 0.23 mm Hg. This material was reesterified with benzyl alcohol using the method described above. Analysis of this ester by HPLC on a chiral column indicated that the ester was about 85% the (R)-enantion, and about 15% of the (S)-enantiomer. This mixture of benzyl esters was resubjected to enzymatic resolution using the method detailed above. Work-up of the product of this enzymatic process in the manner described above yielded, after vacuum distillation, 47.8 g of (R)-tetrahydro-2-furoic acid in two fractions: Fraction 1: B.p.73-77'C at 0.35 mm Hg; ηD 25 = 1.4595; [a]D 25 = +32.85° (C = 1, CHCl3); Fraction 2: 36.8 g; 35.93 g; b.p. 77-78°C at 0.4 mm Hg; ηD 25 = 1.4595; [a]D 25 = +33.39° (C = 1, CHCl3). Step 3 - Preparation of R(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine, hydrochloride dihydrate The title compound was prepared from the enzymatically-resolved (R)-tetrahydro-2-furoic acid using the methods of Step 3 of Example 1 and Example 2. [a]D 24 = + 25.33° (C = 1, H2O). Example 4 Preparation of S(-)-2-[4-[(tetrahvdro-2-furanyl)carbonyl]-1-piperazinyl]-6.7-dimethoxy-4- quinazolinamine Step 1 - Preparation of S(-)-tetrahydrofuroic acid Using the procedure detailed in Can. J. Chem.. 61:1383-1386 (1983), racemic tetrahydro2-furoic acid was first converted to a mixture of the diastereomeric ephedrine salts by reaction with (+)-ephedrine in ethyl acetate. The crude S(-)-ephedrine salt which first precipitated had a melting point of 114-115°C. The material was recrystallized four times from ethyl acetate to yield material melting at 115-117°C and having an optical rotation [a]D 26.5ºC = +13.4° (C=1, methanol) (literature [a]D - + 13.8°). The salt was acidified to recover the 5(-)-tetrahydro-2-furoic acid, b.p. 60°C at 0.5 mm Hg, refractive index, hD 25 = 1.4582, optical rotation [ a]D 22 = -32.02º (C=1, chloroform) (literature [a]D = -30.1° (C=1, chloroform)). Step 2 - Preparation of S(-)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6.7-dimethoxy-4-quinazolinamine The procedure employed was the same as that described above in Example 1 for the R(+)-enantiomer, yielding S(-)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine, m.p. 269.5-271.1ºC, optical rotation [a]D 22ºC = -26.9° (C=1, 3N hydrochloric acid). Example 5 Preparation of S(-)-2-[4-[(tetrahydro-2-furanyl)carbonyl]- 1 -piperazinyl]-6.7-dimethoxy-4- quinazolinamine. hydrochloride salt dihydrate The procedure employed was the same as in Example 2 for the preparation of the hydrochloride salt of the R(+)-enantiomer. M.p.271.5-273'C (dec), optical rotation [a]D 28.5ºC = -23.1° (C=1, water). Example 6 Determination of the Optical Purity of R(+) -Terazosin The material of Examples 2 and 3 was analyzed for optical purity by separation of the R(+)- and S(-)-enantiomers on a chiral AGP column (α1 acid glycoprotein column, ChromTech, Box 512, S-14563 Norsberg, Sweden). The mobile phase consisted of 50 mM potassium phosphate at pH 7.4 and acetonitrile in a ratio of 94/6. The flow rate was 0.9 ml/min. The mobile phase was equilibrated at 0°C-6°C. Detection of the eluate was by ultraviolet light at 254 nM. Samples of 5μl containing 0.1 mg/ml of compound were employed. Example Optical Rotation Percent R(+)-Enantiomer 2 + 23.94° 91 3 + 25.33° >99
While there have been described and illustrated what are believed to be the preferred embodiments of the present invention, it will be obvious to one of ordinary skill in the art that various modifications thereof can be made without departing from the scope of the invention as it is defined by the appended claims.

Claims (10)

WE CLAIM:

1. The compound having the name R(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]- 6,7-dimethoxy-4-quinazolinamine or a pharmaceutically acceptable salt thereof substantially free of the S(-)-enantiomer.

2. The compound having the name R(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]- 6,7-dimethoxy-4-quinazolinamine having an optical rotation of at least [a]D 22ºC = 34.83°
(C=1, 3N hydrochloric acid).

3. The compound having the name R(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]- 6,7-dimethoxy-4-quinazolinamine hydrochloride dihydrate substantially free of the S(-)- enantiomer.

4. The compound as defined by Claim 3 having an optical rotation of at least [α]D 28.5ºC (C=1, water) of +23.9°.

5. A pharmaceutical composition comprising a therapeutically effective amount of R(+)-2-[4[(tetrahydro-2-furanyl)carbonyl]-1-piperazmyl]-6,7-dimethoxy-4-quinazolinamine or a pharmaceutically acceptable salt thereof substantially free of the S(-)-enantiomer. in combination with a pharmaceutically acceptable carrier.

6. A method of treating disease states modulated by α1 adrenergic activity in a mammal in need of such treatment while minimizing unwanted side effects resulting from α2 adrenergic activity comprising administering a therapeutically effective amount of R(+)-2 [4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimeώoxy-4-quinazolinamine or a pharmaceutically acceptable salt thereof substantially free of the S(-)-enantiomer.

7. A method of treating disease states modulated by α1 adrenergic activity in a mammal in need of such treatment without undesirable heart rate increase resulting from α2 adrenergic activity comprising administering a therapeutically effective amount of R(+)-2-
[4-[(tetrahydro-2-furanyl)carbonyl]- 1 -piperazinyl]-6,7-dimethoxy-4-quinazolinamine or a pharmaceutically acceptable salt thereof substantially free of the S(-)-enantiomer.

8. A method of treating disease states modulated by α1 adrenergic activity in a mammal in need of such treatment without undesirable cardiac contractility increase resulting from α2 adrenergic activity comprising administering a therapeutically effective amount of R(+)-2- [4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine or a pharmaceutically acceptable salt thereof substantially free of the S(-)-enantiomer.

9. A method of treating hypertension in a mammal in need of such treatment comprising
administering a therapeutically effective amount of R(+)-2-[4-[(tetrahydro-2- furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine or a pharmaceutically acceptable salt thereof substantially free of the S(-)-enantiomer.

10. A method of treating benign prostatic hyperplasia in a mammal in need of such treatment comprising administering a therapeutically effective amount of R(+)-2-[4-[(tetrahydro-2- furanyl)carbonyl]-1-piperazinyl]-6,7-dimemoxy-4-quinazolinamine or a pharmaceutically acceptable salt thereof substantially free of the S(-)-enantiomer.

AU83231/91A
1990-06-29
1991-06-26
R(+)-terazosin

Ceased

AU654148B2
(en)

Applications Claiming Priority (4)

Application Number
Priority Date
Filing Date
Title

US546349

1990-06-29

US07/546,349

US5212176A
(en)

1990-06-29
1990-06-29
R(+)-terazosin

PCT/US1991/004562

WO1992000073A1
(en)

1990-06-29
1991-06-26
R(+)-terazosin

CA002086974A

CA2086974C
(en)

1990-06-29
1993-01-08
R(+)-terazosin

Publications (2)

Publication Number
Publication Date

AU8323191A
true

AU8323191A
(en)

1992-01-23

AU654148B2

AU654148B2
(en)

1994-10-27

Family
ID=25675811
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU83231/91A
Ceased

AU654148B2
(en)

1990-06-29
1991-06-26
R(+)-terazosin

Country Status (14)

Country
Link

US
(1)

US5212176A
(en)

EP
(1)

EP0536329B1
(en)

JP
(1)

JPH07119222B2
(en)

AT
(1)

ATE136779T1
(en)

AU
(1)

AU654148B2
(en)

CA
(1)

CA2086974C
(en)

DE
(1)

DE69118889T2
(en)

DK
(1)

DK0536329T3
(en)

ES
(1)

ES2089224T3
(en)

GR
(1)

GR3020364T3
(en)

IE
(1)

IE72967B1
(en)

IL
(1)

IL98562A
(en)

PT
(1)

PT98148B
(en)

WO
(1)

WO1992000073A1
(en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

NZ241979A
(en)

1991-03-20
1996-01-26
Merck & Co Inc
Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker

JPH08502977A
(en)

1992-11-04
1996-04-02
セプラコア，インコーポレイテッド

Method for treating benign prostatic hyperplasia and atherosclerosis and (+) doxazosin composition

JPH08502981A
(en)

1992-11-04
1996-04-02
セプラコア，インコーポレイテッド

Method for treating hypertension and composition of (+) doxazosin

US5294615A
(en)

1993-04-29
1994-03-15
Abbott Laboratories
Terazosin polymorph and pharmaceutical composition

US5412095A
(en)

1993-04-29
1995-05-02
Abbott Laboratories
Terazosin monohydrochloride and processes and intermediate for its production

US5504207A
(en)

1994-10-18
1996-04-02
Abbott Laboratories
Process and intermediate for the preparation of terazosin hydrochloride dihydrate

US5587377A
(en)

1995-10-24
1996-12-24
Invamed, Inc.
Terazosin crystalline polymorph and pharmaceutical compositions thereof

JPH11507395A
(en)

1995-11-15
1999-06-29
メルクエンドカンパニーインコーポレーテッド

Alpha 1a adrenergic receptor antagonist

DE19546573A1
(en)

1995-12-13
1997-06-19
Uetikon Chemie Gmbh

Crystalline polymorph of terazosin hydrochloride, and process for its preparation

US5952003A
(en)

1996-08-01
1999-09-14
Novartis Corporation
Terazosin capsules

US5922722A
(en)

1996-11-12
1999-07-13
Merck & Co., Inc.
Alpha 1a adrenergic receptor antagonists

IT1286789B1
(en)

1996-11-29
1998-07-17
Alfa Chem Ital

PROCESS FOR THE PRODUCTION OF FORM I OF ANHYDROUS MONOCLORIDATE TERAZOSIN

GB9708917D0
(en)

1997-05-01
1997-06-25
Pfizer Ltd
Compounds useful in therapy

US6143750A
(en)

1997-06-18
2000-11-07
Merck & Co., Inc.
Alpha 1a adrenergic receptor antagonists

US6037354A
(en)

1997-06-18
2000-03-14
Merck & Co., Inc.
Alpha 1a adrenergic receptor antagonists

US6214832B1
(en)

1997-06-18
2001-04-10
Merck & Co., Inc.
Bis-piperidinyl-pyrimidin-2-ones as alpha 1a adrenergic receptor antagonists

US6057350A
(en)

1997-06-18
2000-05-02
Merck & Co., Inc.
Alpha 1a adrenergic receptor antagonists

US6080760A
(en)

1997-06-18
2000-06-27
Merck & Co., Inc.
Alpha 1A adrenergic receptor antagonists

US6376503B1
(en)

1997-06-18
2002-04-23
Merck & Co., Inc
Alpha 1a adrenergic receptor antagonists

US6248888B1
(en)

1997-11-14
2001-06-19
Teva Pharmaceutical Industries Ltd.
Process for the preparation of terazosin hydrochloride dihydrate

AU5234899A
(en)

1998-07-30
2000-02-21
Merck & Co., Inc.
Alpha 1a adrenergic receptor antagonists

WO2000025782A1
(en)

1998-10-29
2000-05-11
Merck & Co., Inc.
Dihydropyridinones and pyrrolinones useful as alpha 1a adrenoceptor antagonists

US6228870B1
(en)

1998-11-10
2001-05-08
Merck & Co., Inc.
Oxazolidinones useful as alpha 1a adrenoceptor antagonists

US6319932B1
(en)

1998-11-10
2001-11-20
Merck & Co., Inc.
Oxazolidinones useful as alpha 1A adrenoceptor antagonists

WO2000029386A1
(en)

1998-11-12
2000-05-25
Merck & Co., Inc.
Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists

DE19856441C5
(en)

1998-12-08
2004-11-18
Robert Bosch Gmbh

Procedure for the transmission of short messages

DE19856440C2
(en)

1998-12-08
2002-04-04
Bosch Gmbh Robert

Transmission frame and radio unit with transmission frame

US6358959B1
(en)

1999-01-26
2002-03-19
Merck & Co., Inc.
Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists

GB2355457A
(en)

1999-09-30
2001-04-25
Merck & Co Inc
Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists

GB2355456A
(en)

1999-09-30
2001-04-25
Merck & Co Inc
Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists

GB2355263A
(en)

1999-09-30
2001-04-18
Merck & Co Inc
Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists

GB2355264A
(en)

1999-09-30
2001-04-18
Merck & Co Inc
Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists

US6200573B1
(en)

1999-12-03
2001-03-13
Starcor Pharmaceuticals, Inc.
Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia

US6313172B1
(en)

2000-04-13
2001-11-06
Allergan Sales, Inc.
Methods and compositions for modulating alpha adrenergic receptor activity

US7335803B2
(en)

2001-10-19
2008-02-26
Allergan, Inc.
Methods and compositions for modulating alpha adrenergic receptor activity

JP2002121188A
(en)

2000-07-18
2002-04-23
Toray Ind Inc
Method for manufacturing piperazine amide compound and piperazine-tetrahydrofuran-2-carboxylic acid amide derivative

US20020198215A1
(en)

2000-10-23
2002-12-26
Lino Tavares
Terazosin transdermal device and methods

US6534542B2
(en)

2001-02-27
2003-03-18
Allergen Sales, Inc.
(2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors

AU2003217676B2
(en)

2002-02-22
2009-06-11
Takeda Pharmaceutical Company Limited
Active agent delivery systems and methods for protecting and administering active agents

US7323485B2
(en)

2002-05-21
2008-01-29
Allergan, Inc.
4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds

US7358269B2
(en)

2002-05-21
2008-04-15
Allergan, Inc.
2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one

US7091232B2
(en)

2002-05-21
2006-08-15
Allergan, Inc.
4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds

US7276522B2
(en)

2002-05-21
2007-10-02
Allergan, Inc.
4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds

AU2004279336A1
(en)

2003-09-12
2005-04-21
Allergan, Inc.
Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions

US7390829B2
(en)

2005-06-29
2008-06-24
Allergan, Inc.
Alpha-2 adrenergic agonists

US7323477B2
(en)

2006-02-02
2008-01-29
Allergan, Inc.
7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline

WO2008021891A2
(en)

2006-08-08
2008-02-21
Auspex Pharmaceuticals, Inc.
Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects

US7598417B2
(en)

2007-04-12
2009-10-06
Allergan, Inc.
Substituted fluoroethyl ureas as alpha 2 adrenergic agents

PL2155733T3
(en)

2007-05-23
2013-02-28
Allergan Inc
Cyclic lactams for the treatment of glaucoma or elevated intraocular pressure

EP2160386B1
(en)

2007-05-23
2012-07-11
Allergan, Inc.
Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds

US7902247B2
(en)

2008-01-09
2011-03-08
Allergan, Inc.
Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors

US7829587B2
(en)

2008-01-09
2010-11-09
Allergan, Inc.
Substituted 2-aminotetralin derivatives as selective alpha 2B agonist

US8809379B2
(en)

2008-01-18
2014-08-19
Allergan, Inc.
Selective subtype alpha 2 adrenergic agents and methods for use thereof

US8362022B2
(en)

2008-01-18
2013-01-29
Allergan, Inc.
Selective subtype alpha 2 adrenergic agents and methods for use thereof

US20090239918A1
(en)

2008-03-24
2009-09-24
Allergan, Inc.
Selective subtype alpha 2 adrenergic agents and methods for use thereof

US9072727B2
(en)

2008-04-18
2015-07-07
Warsaw Orthopedic, Inc.
Alpha adrenergic receptor agonists for treatment of degenerative disc disease

US8420114B2
(en)

2008-04-18
2013-04-16
Warsaw Orthopedic, Inc.
Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation

AU2009244536A1
(en)

2008-05-05
2009-11-12
Allergan, Inc.
Alpha2B and alpha2C agonists

JP5710470B2
(en)

2008-05-16
2015-04-30
アラーガンインコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ

Selective subtype alpha 2 adrenergic agents and methods of use thereof

AU2009333620A1
(en)

2008-12-08
2011-07-07
Allergan, Inc.
N-(1-phenyl-2-arylethyl)-4,5-dihydro-3H-pyrrol-2-amine compounds as subtype selective modulators of alpha2B or alpha2B and alpha2C adrenoceptors

US20110306635A1
(en)

2009-02-06
2011-12-15
Allergan ,Inc.
Pyridine compounds as subtype selective modulators of alpha2b and /or alpha 2c adrenergic receptors

WO2011014332A1
(en)

2009-07-30
2011-02-03
Allergan, Inc.
Selective alpha 2b/2c agonists

WO2011044229A1
(en)

2009-10-06
2011-04-14
Allergan, Inc.
2h-pyrrol-5-amine derivatives as alpha adrenergic receptor modulators

US20160361380A1
(en)

2015-06-12
2016-12-15
Nymox Corporation
Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations

US11224572B1
(en)

2020-08-17
2022-01-18
Novitium Pharma LLC
Stable oral liquid composition of terazosin

Family Cites Families (3)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US4026894A
(en)

1975-10-14
1977-05-31
Abbott Laboratories
Antihypertensive agents

GB1591490A
(en)

1977-08-04
1981-06-24
Abbott Lab
1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride dihydrate

JPH01216983A
(en)

1988-02-26
1989-08-30
Hiroyuki Nohira
Method for optical resolution of (+-)-tetrahydrofuran-2-carboxylic acid

1990

1990-06-29
US
US07/546,349
patent/US5212176A/en
not_active
Expired – Fee Related

1991

1991-06-18
IE
IE208691A
patent/IE72967B1/en
not_active
IP Right Cessation

1991-06-19
IL
IL9856291A
patent/IL98562A/en
not_active
IP Right Cessation

1991-06-26
JP
JP3513458A
patent/JPH07119222B2/en
not_active
Expired – Fee Related

1991-06-26
EP
EP91914562A
patent/EP0536329B1/en
not_active
Expired – Lifetime

1991-06-26
DK
DK91914562.3T
patent/DK0536329T3/en
active

1991-06-26
WO
PCT/US1991/004562
patent/WO1992000073A1/en
active
IP Right Grant

1991-06-26
DE
DE69118889T
patent/DE69118889T2/en
not_active
Expired – Fee Related

1991-06-26
ES
ES91914562T
patent/ES2089224T3/en
not_active
Expired – Lifetime

1991-06-26
AT
AT91914562T
patent/ATE136779T1/en
not_active
IP Right Cessation

1991-06-26
AU
AU83231/91A
patent/AU654148B2/en
not_active
Ceased

1991-06-28
PT
PT98148A
patent/PT98148B/en
not_active
IP Right Cessation

1993

1993-01-08
CA
CA002086974A
patent/CA2086974C/en
not_active
Expired – Fee Related

1996

1996-06-27
GR
GR960401733T
patent/GR3020364T3/en
unknown

Also Published As

Publication number
Publication date

IL98562A
(en)

1995-12-31

EP0536329B1
(en)

1996-04-17

JPH07119222B2
(en)

1995-12-20

PT98148B
(en)

1998-12-31

DE69118889T2
(en)

1996-11-07

EP0536329A1
(en)

1993-04-14

CA2086974A1
(en)

1994-07-09

GR3020364T3
(en)

1996-09-30

AU654148B2
(en)

1994-10-27

IE912086A1
(en)

1992-01-01

PT98148A
(en)

1993-08-31

DK0536329T3
(en)

1996-08-12

WO1992000073A1
(en)

1992-01-09

EP0536329A4
(en)

1993-05-19

ATE136779T1
(en)

1996-05-15

US5212176A
(en)

1993-05-18

IE72967B1
(en)

1997-05-07

DE69118889D1
(en)

1996-05-23

ES2089224T3
(en)

1996-10-01

JPH05507280A
(en)

1993-10-21

CA2086974C
(en)

2001-04-10

Contact information